Communiqués Monte Rosa Therapeutics, Inc.

Actions

GLUE

US61225M1027

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
14,07 ^USD	-1,75 %		+1,66 %	-10,27 %

08/09	Principales actualités de la mi-journée : GE Aerospace va acquérir Consolidated Precision Products ; Qualcomm émet des bons de souscription d'actions au profit d'Amazon	MT
08/09	Monte Rosa Therapeutics lance une étude clinique de phase 2 pour le MRT-6160 (Ddy391), un dégradeur de colle moléculaire ciblant Vav1	CI

Communiqués

08/09	Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)	GL
02/09	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
01/09	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	GL
24/08	Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	GL
06/08	Monte Rosa Therapeutics: Q2 Earnings Snapshot	AQ
06/08	Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates	GL
02/07	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
02/06	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
20/05	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	AQ
07/05	Monte Rosa Therapeutics: Q1 Earnings Snapshot	AQ
07/05	Monte Rosa Therapeutics : Corporate Presentation – May 2026	PU
07/05	Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates	AQ
05/05	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
22/04	Monte Rosa Therapeutics : AACR 2026 – Selective targeting of CCNE1 using molecular glue degraders for the treatment of CCNE1 amplified cancers	PU
20/04	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors	GL
17/03	Monte Rosa Therapeutics: Q4 Earnings Snapshot	AQ
17/03	Monte Rosa Therapeutics : Corporate Presentation – March 2026	PU
17/03	Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates	AQ
16/03	Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer	AQ
26/02	Monte Rosa Therapeutics : Corporate Presentation – February 2026	PU
26/02	Monte Rosa Therapeutics : ASCO Genitourinary Cancers Symposium 2026 – MRT-2359 in Combination with Enzalutamide Suppresses Multiple Oncogenic Pathways to Drive Deep and Durable PSA and RECIST Responses in Heavily Pretreated, Metastatic Castration-Resistant Prostate Cancer Harbori	PU
24/02	Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)	AQ
23/02	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	AQ
22/01	Monte Rosa Therapeutics : Keystone Symposia – MRT-6160, a highly selective and first-in-class VAV1-directed molecular glue degrader, demonstrates activity in multiple immune-mediated disease models	PU
09/01	Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering	AQ